Jacobs Levy Equity Management’s Niagen Bioscience NAGE Stock Holding History

Jacobs Levy Equity Management’s Portfolio NAGE Stock Details NAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	+324,690	New	+$1.32M	﹤0.01%	704

Other funds holding NAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SteelPeak Wealth Woodland Hills, California $3.86B AUM 48.92% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TCM

Tieton Capital Management Yakima, Washington $348M AUM 45.13% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jacobs Levy Equity Management's NAGE Position: Q2 2026 in Review

Jacobs Levy Equity Management opened a new position in Niagen Bioscience (NAGE) in Q2 2026: 324,690 shares worth $1.04M. The stake represents ﹤0.01% of the portfolio and ranks #704 among its holdings.

140 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.

Jacobs Levy Equity Management held 324,690 shares of Niagen Bioscience worth $1.04M as of Q2 2026.
Niagen Bioscience was a new Jacobs Levy Equity Management position in Q2 2026.
Niagen Bioscience made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q2 2026, its #704 holding.
140 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.